{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:18:18Z","timestamp":1792293498352,"version":"4.4.0"},"reference-count":31,"publisher":"The Endocrine Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9,1]]},"DOI":"10.1210\/jc.2017-00816","type":"journal-article","created":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T14:09:10Z","timestamp":1497017350000},"page":"3278-3287","source":"Crossref","is-referenced-by-count":156,"title":["Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma"],"prefix":"10.1210","volume":"102","author":[{"given":"Grace","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Grozinsky-Glasberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Callahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amichay","family":"Meirovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofra","family":"Maimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Pattison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2017,6,9]]},"reference":[{"issue":"12","key":"key\n\t\t\t\t20170906135617_B1","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00259-012-2215-8","article-title":"EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"39","author":"European Association of Nuclear Medicine","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"20","key":"key\n\t\t\t\t20170906135617_B2","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1093\/hmg\/ddr324","article-title":"Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma","volume":"20","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"1","key":"key\n\t\t\t\t20170906135617_B3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/path.4503","article-title":"The genomic landscape of phaeochromocytoma","volume":"236","year":"2015","journal-title":"J Pathol"},{"issue":"2","key":"key\n\t\t\t\t20170906135617_B4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1677\/ERC-08-0284","article-title":"Clinical aspects of SDHx-related pheochromocytoma and paraganglioma","volume":"16","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"key\n\t\t\t\t20170906135617_B5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1677\/ERC-10-0211","article-title":"Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma","volume":"18","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"key\n\t\t\t\t20170906135617_B6","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1677\/ERC-07-0074","article-title":"The diagnosis and management of malignant phaeochromocytoma and paraganglioma","volume":"14","year":"2007","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"key\n\t\t\t\t20170906135617_B7","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.2967\/jnumed.108.058701","article-title":"Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial","volume":"50","year":"2009","journal-title":"J Nucl Med"},{"issue":"4","key":"key\n\t\t\t\t20170906135617_B8","doi-asserted-by":"crossref","first-page":"T135","DOI":"10.1530\/ERC-15-0175","article-title":"15 years of paraganglioma: imaging and imaging-based treatment of pheochromocytoma and paraganglioma","volume":"22","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"key\n\t\t\t\t20170906135617_B9","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1507\/endocrj.EJ14-0211","article-title":"Effects and safety of 131I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry","volume":"61","author":"Drafting Committee for Guidelines on Internal Radiotherapy with131I-MIBG","year":"2014","journal-title":"Endocr J"},{"issue":"4","key":"key\n\t\t\t\t20170906135617_B10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis","volume":"80","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"25","key":"key\n\t\t\t\t20170906135617_B11","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"key\n\t\t\t\t20170906135617_B12","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1210\/jc.2008-2697","article-title":"Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy","volume":"94","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"key\n\t\t\t\t20170906135617_B13","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key\n\t\t\t\t20170906135617_B14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40644-016-0084-2","article-title":"(68)Ga-DOTATATE and (18)F-FDG PET\/CT in paraganglioma and pheochromocytoma: utility, patterns and heterogeneity","volume":"16","year":"2016","journal-title":"Cancer Imaging"},{"issue":"2","key":"key\n\t\t\t\t20170906135617_B15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2967\/jnumed.115.161018","article-title":"68Ga-DOTATATE PET\/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT\/MRI","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"issue":"10","key":"key\n\t\t\t\t20170906135617_B16","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1007\/s00259-016-3357-x","article-title":"PET\/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT\/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"key\n\t\t\t\t20170906135617_B17","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s00259-015-3268-2","article-title":"Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET\/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"key\n\t\t\t\t20170906135617_B18","unstructured":"Hicks\n              RJ\n            , KwekkeboomDJ, KrenningE, BodeiL, Grozinsky-GlasbergS, ArnoldR, BorbathI, CwiklaJ, ToumpanakisC, KaltsasG, DaviesP, H\u00f6rschD, Tiensuu JansonE, RamageJ; all other Antibes Consensus Conference participants. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues [published online ahead of print April 13, 2017]. Neuroendocrinology."},{"issue":"2","key":"key\n\t\t\t\t20170906135617_B19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"NETTER-1 Trial Investigators","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"key\n\t\t\t\t20170906135617_B20","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1055\/s-0032-1311637","article-title":"Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL)","volume":"44","year":"2012","journal-title":"Hormone Metab Res"},{"issue":"4","key":"key\n\t\t\t\t20170906135617_B21","first-page":"334","article-title":"Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma","volume":"52","year":"2008","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"5","key":"key\n\t\t\t\t20170906135617_B22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12032-016-0737-9","article-title":"Peptide receptor radionuclide therapy for metastatic paragangliomas","volume":"33","year":"2016","journal-title":"Med Oncol"},{"issue":"8","key":"key\n\t\t\t\t20170906135617_B23","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00259-015-3029-2","article-title":"Peptide receptor radionuclide therapy with (90)Y\/(177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours)","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"key\n\t\t\t\t20170906135617_B24","first-page":"1599","article-title":"Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma","volume":"47","year":"2006","journal-title":"J Nucl Med"},{"key":"key\n\t\t\t\t20170906135617_B25","first-page":"S219","article-title":"Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide","volume":"31","year":"1999","journal-title":"Ital J Gastroenterol Hepatol"},{"issue":"2","key":"key\n\t\t\t\t20170906135617_B26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","year":"2009","journal-title":"Eur J Cancer"},{"issue":"17","key":"key\n\t\t\t\t20170906135617_B27","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1158\/1078-0432.CCR-15-1073","article-title":"Moving beyond \u201clumpology\u201d: PET\/CT imaging of pheochromocytoma and paraganglioma","volume":"21","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"3","key":"key\n\t\t\t\t20170906135617_B28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s13139-015-0332-6","article-title":"The challenges of treating paraganglioma patients with (177)Lu-DOTATATE PRRT: catecholamine crises, tumor lysis syndrome and the need for modification of treatment protocols","volume":"49","year":"2015","journal-title":"Nucl Med Mol Imaging"},{"issue":"3","key":"key\n\t\t\t\t20170906135617_B29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1530\/EJE-07-0778","article-title":"Pheochromocytoma crisis induced by glucocorticoids: a report of four cases and review of the literature","volume":"158","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"key\n\t\t\t\t20170906135617_B30","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12149-014-0843-8","article-title":"Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors","volume":"28","year":"2014","journal-title":"Ann Nucl Med"},{"issue":"4","key":"key\n\t\t\t\t20170906135617_B31","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/jso.24553","article-title":"Peptide receptor radionuclide treatment and (131)I-MIBG in the management of patients with metastatic\/progressive phaeochromocytomas and paragangliomas","volume":"115","year":"2017","journal-title":"J Surg Oncol"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/102\/9\/3278\/19703499\/jc.2017-00816.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T21:06:18Z","timestamp":1504731978000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jcem\/article\/102\/9\/3278\/3865690\/Efficacy-of-Peptide-Receptor-Radionuclide-Therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,9]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,6,9]]},"published-print":{"date-parts":[[2017,9,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2017-00816","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,9]]}}}